Compare ING Groep NV (ING) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Smith & Nephew plc — how do they compare? ING Groep NV trades at $35.65 (market cap $101.22B), while Smith & Nephew plc trades at $29.82 (market cap $12.54B). The key difference: ING Groep NV is far larger — about 8.1× Smith & Nephew plc's market cap, and ING Groep NV pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| ING | SNN | |
|---|---|---|
Market Cap | $101.22B | $12.54B |
Sector | Financials | Health |
52-Week High | $35.92 | $38.70 |
52-Week Low | $23.66 | $28.73 |
Dividend Yield | 3.73% | 2.65% |
Enterprise Value | — | $15.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING Groep (ING) trades at $35.61, up 1.05% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $0.79 exceeding expectations. Revenue growth remains stable at $22.9B for 2025, supported by a robust 28.34% net income margin and 13.49% ROE. Recent guidance upgrades and strategic acquisitions in wealth management signal management confidence in future growth prospects.
The outlook remains positive with 62.5% analyst buy ratings and technical indicators supporting further upside. Key risks include negative operating cash flows and European banking sector volatility. The stock's attractive 13.24 P/E ratio and dividend yield provide value appeal, though investors should monitor cash flow trends and interest rate sensitivity.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
